Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | JUN | P05412 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.45 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.45 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17791879 | 0.85 | MAPT (0.55) | MAPTLMNASMN1; SMN2MAPK1KDM4E | |
| SCHEMBL11484627 | 0.85 | MAPT (0.55) | MAPTLMNASMN1; SMN2MAPK1KDM4E | |
| SCHEMBL11484623 | 0.85 | MAPT (0.55) | MAPTLMNASMN1; SMN2MAPK1KDM4E | |
| SCHEMBL3682708 | 0.82 | MEN1 (0.56) | LMNASMN1; SMN2KDM4EALDH1A1KMT2A | |
| SCHEMBL186729 | 0.82 | MEN1 (0.56) | LMNASMN1; SMN2KDM4EALDH1A1KMT2A | |
| SCHEMBL187458 | 0.82 | MEN1 (0.56) | LMNASMN1; SMN2KDM4EALDH1A1KMT2A | |
| SCHEMBL3225999 | 0.82 | MAPT (0.78) | MAPTLMNASMN1; SMN2MAPK1KDM4E | |
| SCHEMBL8430296 | 0.80 | MEN1 (0.47) | MAPTLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL8430294 | 0.80 | MEN1 (0.47) | MAPTLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10373700 | 0.79 | MAPT (0.74) | MAPTLMNASMN1; SMN2MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246907-A1 | PYRIDOMYCIN BASED COMPOUNDS EXHIBITING AN ANTITUBERCULAR ACTIVITY | ETH ZURICH (CH) | 2015-09-03 | — | — | US | disclosed |
| US-20150246907-A1 | PYRIDOMYCIN BASED COMPOUNDS EXHIBITING AN ANTITUBERCULAR ACTIVITY | ETH ZURICH (CH) | 2015-09-03 | — | — | US | disclosed |
| WO-2014040709-A1 | PYRIDOMYCIN BASED COMPOUNDS EXHIBITING AN ANTITUBERCULAR ACTIVITY | ETH ZURICH (CH) | 2014-03-20 | — | — | WO | disclosed |
| US-8067642-B2 | Chiral phosphorous compounds | Celtice Catalysts Limited, Nova UCD (IE) | 2011-11-29 | — | — | US | disclosed |
| US-20100168456-A1 | CHIRAL PHOSPHOROUS COMPOUNDS | CELTIC CATALYSTS LIMITED (IE) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168456-A1 | CHIRAL PHOSPHOROUS COMPOUNDS | RPP30, PLCB3, INPP5D | MAPT 4587/4885LMNA 4020/4885SMN1; SMN2 4509/4885 |
| US-20150246907-A1 | PYRIDOMYCIN BASED COMPOUNDS EXHIBITING AN ANTITUBERCULAR ACTIVITY | NR1H2, NR1H3, NR4A1 | MAPT 3630/4885LMNA 2270/4885SMN1; SMN2 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.